Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuroendocrine Tumor (NET) and RLT Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SSTR2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | SSTR2 Promise-ORF / Lentivirus Particles Full-length GPCR, CMV promoter, HEK293T packaged. Sequence Verified. For stable cell line generation preserving native 7-TM conformation. |
View SSTR2 Products |
| Antigen | SSTR2 Full-Length Lentivirus (Native Glycosylation) & ECD-Fc Fusion Protein HEK293 expressed. Endotoxin <1 EU/ug. Theoretical MW verified. Cell-based assays preserve native topology. |
View SSTR2 Products |
| Benchmark Ab | Anti-SSTR2 Recombinant / Reference Antibody Sequence verified. Research grade monoclonal for flow cytometry, receptor occupancy, and assay positive control. High purity (>95%). |
View SSTR2 Products |
| Validator | SSTR2 siRNA Set Three unique sequences for knockdown verification and target specificity screening. Sequence verified, endotoxin controlled. |
View SSTR2 Products |
| Related Target: SSTR1 | Subfamily homolog for counter-screening and cross-reactivity profiling. | View SSTR1 Products |
| Related Target: SSTR5 | Co-expressed GPCR in neuroendocrine tumors; critical subtype selectivity screening and pan-SSTR therapeutic strategy. | View SSTR5 Products |
| Related Target: CXCR4 | Synergistic pathway in NET metastasis; combination therapy target for radioligand therapy. | View CXCR4 Products |
| Related Target: IGF1R | Downstream pathway node; combination therapy target for NET resistance. | View IGF1R Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native GPCR Conformation & Folding | HEK293 expressed full-length lentivirus or stable cell lines preserve native glycosylation and 7-TM topology, essential for ligand binding assays. |
| Subfamily Selectivity (SSTR1/3/4/5) | Human SSTR family ortholog protein/lentivirus panel available; sequence verified by mass spec for definitive cross-reactivity counter-screening. |
| Species Cross-reactivity (Cyno/Mouse) | Human/Mouse/Cyno SSTR2 lentivirus particles available; sequence identity >95% for translational toxicology. |
| Internalization Kinetics | High-titer lentivirus (10^8 TU/mL) enables stable cell lines for quantitative flow cytometry and confocal internalization assays. |
| Ligand Competition Assays | Endotoxin-controlled ECD-Fc fusion (<1 EU/ug) suitable for SPR and ELISA with peptide radioligands. |
| Lack of Positive Controls | Sequence-verified recombinant benchmark antibodies and native ligand controls available for flow cytometry and functional assays. |
| False Positives / Target Specificity | Validated siRNA sets included for orthogonal specificity checks and knockdown baseline mapping. |
Live SSTR2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SSTR2 therapeutics is intensifying, with major players shifting focus from traditional somatostatin analogs (SSAs) to next-generation Radioligand Therapy (RLT) and Antibody-Drug Conjugates (ADCs). Novartis (Lutathera, 177Lu-DOTATATE) dominates the GEP-NET space; recent mega-deals including BMS's acquisition of RayzeBio (RYZ101, 225Ac-DOTATATE) and Lilly's purchase of Point Biopharma signal strong pharma interest in alpha-emitter RLT. The next wave targets alpha-emitters (Ac-225, Pb-212), oral non-peptide agonists for improved patient compliance (e.g., Crinetics' CRN00808), and bispecific radioligands. Key trends include: (1) paradigm shift from agonists to antagonists (e.g., JR11) for higher tumor uptake and longer retention; (2) combination therapy (RLT + checkpoint inhibitors or PARP inhibitors) to overcome resistance; (3) theranostics expansion where diagnostic (68Ga-DOTATATE) and therapeutic (177Lu-DOTATATE) pairs guide precision treatment. Future R&D will focus on overcoming SSTR2 downregulation, CXCR4-upregulated escape pathways, and renal toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Radioligand Therapy (PRRT) | Novartis, ITM Isotope Technologies, RayzeBio (BMS), Point Biopharma (Lilly) | GEP-NETs, Pheochromocytoma, SCLC | Internalization Assay (Need full-length SSTR2 cell lines for receptor binding and internalization kinetics) |
| ADC | Daiichi Sankyo, Sanofi, Tarveda, Amgen, AstraZeneca | Solid Tumors, SCLC | Target Engagement & Selectivity (Need SSTR2 vs SSTR5 cross-reactivity panel) + Internalization Assay |
| Oral Small Molecule Agonist | Crinetics Pharmaceuticals | Acromegaly, NETs | Functional Assay (Need cAMP inhibition assays in SSTR2-stable cells) |
| Alpha-Emitter RLT | Bayer, Radiomedix | Advanced NETs | Biodistribution Specificity (Need species-cross reactive binding validation) |
| Bispecific / Cell Engager | Xencor, Boehringer Ingelheim | Refractory NETs | Heterodimer / Flow Cytometry Validation (Need cross-reactive Abs and SSTR2-expressing cells) |